These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 32292094)

  • 1. The limits and challenges of antiobesity pharmacotherapy.
    Gadde KM; Atkins KD
    Expert Opin Pharmacother; 2020 Aug; 21(11):1319-1328. PubMed ID: 32292094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice.
    Gadde KM; Pritham Raj Y
    Curr Diab Rep; 2017 May; 17(5):34. PubMed ID: 28378293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of new antiobesity drugs.
    Hainer V
    Expert Opin Pharmacother; 2014 Oct; 15(14):1975-8. PubMed ID: 25100293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of weight-reducing drugs in people with hypertension.
    Siebenhofer A; Winterholer S; Jeitler K; Horvath K; Berghold A; Krenn C; Semlitsch T
    Cochrane Database Syst Rev; 2021 Jan; 1(1):CD007654. PubMed ID: 33454957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current pharmacotherapy for obesity: extrapolation of clinical trials data to practice.
    Gadde KM
    Expert Opin Pharmacother; 2014 Apr; 15(6):809-22. PubMed ID: 24548209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
    Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S
    JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2020 Jan; 13(1):53-64. PubMed ID: 31770497
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term effects of weight-reducing drugs in people with hypertension.
    Siebenhofer A; Jeitler K; Horvath K; Berghold A; Posch N; Meschik J; Semlitsch T
    Cochrane Database Syst Rev; 2016 Mar; 3():CD007654. PubMed ID: 26934640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
    Verpeut JL; Bello NT
    Expert Opin Drug Saf; 2014 Jun; 13(6):831-41. PubMed ID: 24766397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
    Tak YJ; Lee SY
    Curr Obes Rep; 2021 Mar; 10(1):14-30. PubMed ID: 33410104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obesity: The New Global Epidemic Pharmacological Treatment, Opportunities and Limits for Personalized Therapy.
    Milano W; De Biasio V; Di Munzio W; Foggia G; Capasso A
    Endocr Metab Immune Disord Drug Targets; 2020; 20(8):1232-1243. PubMed ID: 32410565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obesity Pharmacotherapy.
    Saunders KH; Umashanker D; Igel LI; Kumar RB; Aronne LJ
    Med Clin North Am; 2018 Jan; 102(1):135-148. PubMed ID: 29156182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phentermine and topiramate extended-release for the obesity: new kids on the block.
    Katsi V; Marketou M; Kallistratos MS; Tousoulis D; Makris T; Manolis AJ; Vardas P; Kallikazaros I
    Recent Pat Cardiovasc Drug Discov; 2013 Apr; 8(1):35-41. PubMed ID: 23565717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modern obesity pharmacotherapy: weighing cardiovascular risk and benefit.
    Cunningham JW; Wiviott SD
    Clin Cardiol; 2014 Nov; 37(11):693-9. PubMed ID: 25223901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapy of obesity: Available medications and drugs under investigation.
    Pilitsi E; Farr OM; Polyzos SA; Perakakis N; Nolen-Doerr E; Papathanasiou AE; Mantzoros CS
    Metabolism; 2019 Mar; 92():170-192. PubMed ID: 30391259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles.
    Krentz AJ; Fujioka K; Hompesch M
    Diabetes Obes Metab; 2016 Jun; 18(6):558-70. PubMed ID: 26936802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of Antiobesity Drugs for Adolescents With Severe Obesity.
    Mital S; Nguyen HV
    JAMA Netw Open; 2023 Oct; 6(10):e2336400. PubMed ID: 37824146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recent progress and novel perspectives on obesity pharmacotherapy].
    Faria AM; Mancini MC; Melo ME; Cercato C; Halpern A
    Arq Bras Endocrinol Metabol; 2010 Aug; 54(6):516-29. PubMed ID: 20857056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reducing the risk of obesity: defining the role of weight loss drugs.
    Ling H; Lenz TL; Burns TL; Hilleman DE
    Pharmacotherapy; 2013 Dec; 33(12):1308-21. PubMed ID: 23712541
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.